Soligenix's dusquetide receives FDA orphan designation for Behcet's disease treatment.

Soligenix's dusquetide, a treatment for Behcet's disease, has received FDA orphan designation. This designation provides Soligenix with incentives and exemptions in the development and marketing of dusquetide. Behcet's disease is a rare and chronic inflammatory disorder that affects the blood vessels, skin, and eyes.

Soligenix Inc. (NASDAQ: SNGX) has received FDA orphan designation for dusquetide, a potential treatment for Behcet's disease. This designation provides the biopharmaceutical company with significant incentives and exemptions in the development and marketing of dusquetide, including tax credits and market exclusivity [1].

Behcet's disease is a rare and chronic inflammatory disorder that primarily affects the blood vessels, skin, and eyes. It is estimated to affect approximately 1 in 100,000 people in the US [2]. The FDA's orphan designation underscores the company's commitment to addressing unmet medical needs in rare diseases. Soligenix's dusquetide is designed to target the inflammatory pathways involved in Behcet's disease, offering a potential new therapeutic option for patients.

The orphan designation follows Soligenix's successful development of HyBryte, a late-stage therapy for cutaneous T-cell lymphoma (CTCL), which has shown promising results in clinical trials. With this designation, Soligenix aims to expand its pipeline of innovative treatments for rare and complex diseases.

References:
[1] https://www.globenewswire.com/news-release/2025/08/08/3130135/0/en/NetworkNewsAudio-Announces-Audio-Press-Release-APR-on-Promising-First-Line-Therapy-for-Rare-Skin-Cancer.html
[2] https://www.globenewswire.com/news-release/2025/08/14/3133146/0/en/Press-Release-Sanofi-s-rilzabrutinib-earns-orphan-designation-in-the-EU-for-IgG4-related-disease.html